EP
MRVI icon

Essential Partners’s Maravai LifeSciences MRVI Stock Holding History

Essential Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56 Sell
9
-7
-44% -$30 ﹤0.01% 2787
2026
Q1 		$45 Buy
+16
New +$54 ﹤0.01% 2789

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Essential Partners's MRVI Position: Q2 2026 in Review

Essential Partners reduced its Maravai LifeSciences (MRVI) stake by 44% in Q2 2026, selling an estimated $30 and leaving 9 shares worth $56. The position accounts for ﹤0.01% of the portfolio, ranked #2787.

Essential Partners first reported a position in MRVI in Q1 2026 and has held it in 2 quarters since. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Essential Partners held 9 shares of Maravai LifeSciences worth $56 as of Q2 2026.
  • Essential Partners sold 7 Maravai LifeSciences shares in Q2 2026, an estimated $30.
  • Maravai LifeSciences made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2787 holding.
  • Essential Partners first reported a position in Maravai LifeSciences in Q1 2026 and has held it in 2 quarters since.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.